ACE and hydrops fetalis: Foundational work from the PARADIGM-HF trial demonstrated that 200 mg twice daily (bid) of SAC/VAL reduced hospitalizations and cardiovascular- and all-cause mortality [1] compared to enalapril (10 mg bid), an angiotensin-converting enzyme inhibitor (ACEi) that is also effective for reducing mortality in HF patients [2].